title: Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
abstract: OBJECTIVE
  Hyperfractionated accelerated radiotherapy without a split (AF) has been performed to improve the local control probability of early glottic carcinomas since 1990 in the authors' institution. Here, they report their experience treating early glottic cancer patients with AF in a single institution who have a long follow-up period.
  
  
  METHODS
  131 T1 N0 M0 glottic cancers and 65 T2 N0 M0 glottic cancers were treated with conventional fractionation (CF) from 1984 to 1989 and with AF since 1990. CF consisted of five daily fractions of 2 Gy per week, to a total dose of 64 Gy. AF consisted of 1.72 Gy per fraction, two fractions per day, 5 days a week, to a total dose of 55 or 58.5 Gy.
  
  
  RESULTS
  The 5-year local control probability for T1 tumors was 94% with 58.5 Gy and 87% with 55 Gy of AF, whereas it amounted to 80% with CF. For T2 tumors, it was 56% with 58.5 Gy and 68% with 55 Gy of AF, whereas it amounted to 64% with CF. The data of T2 should be evaluated with caution due to the small number of patients. Patients with AF had more severe mucosal reactions but no severe late reactions.
  
  
  CONCLUSIONS
  AF significantly improved the local control rates for T1 glottic cancer.
authors.affiliation: Department of Radiology, Sapporo Medical University, School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. sakatako@sapmed.ac.jp
authors.forename: Koh-ichi
authors.initials: K
authors.lastname: Sakata
authors.forename: Masanori
authors.initials: M
authors.lastname: Someya
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hori
authors.forename: Kensei
authors.initials: K
authors.lastname: Nakata
authors.forename: Masaru
authors.initials: M
authors.lastname: Takagi
authors.forename: Masato
authors.initials: M
authors.lastname: Hareyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D005931:Glottis / Q000528:radiation effects; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy; D015996:Survival Rate
chemical_list: D003037:Cobalt Radioisotopes